4//SEC Filing
Lackner Mark 4
Accession 0001725160-25-000041
CIK 0001725160other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 6:32 PM ET
Size
9.1 KB
Accession
0001725160-25-000041
Insider Transaction Report
Form 4
Lackner Mark
Chief Scientific Officer
Transactions
- Award
Common Stock
2025-02-03+335,907→ 527,224 total - Sale
Common Stock
2025-02-03$1.71/sh−14,368$24,591→ 512,856 total - Award
Stock Option (Right to Buy)
2025-02-03+124,714→ 124,714 totalExercise: $1.68Exp: 2035-02-02→ Common Stock (124,714 underlying)
Footnotes (3)
- [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
- [F2]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
- [F3]The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001777413
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 6:32 PM ET
- Size
- 9.1 KB